Effect of β3-adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion-excised rat bladder

被引:1
|
作者
Son, Hee Seo [1 ,2 ]
Moon, Soo Young [3 ]
Kwon, Joonbeom [4 ]
Kim, Jang Hwan [1 ,2 ,5 ,6 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Urol, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Urol Sci Inst, Coll Med, Seoul, South Korea
[3] Korea Univ, Biomed Res Ctr, Ansan Hosp, Ansan, South Korea
[4] Daegu Fatima Hosp, Dept Urol, Daegu, South Korea
[5] Yonsei Univ, Coll Med, Dept Urol, 50-1 Yonsei Ro, Seoul 03722, South Korea
[6] Yonsei Univ, Urol Sci Inst, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
beta 3-adrenoceptor agonist; major pelvic ganglion; micromotions; models; animal; neurons; afferent; overactive bladder; urinary bladder; NON-VOIDING ACTIVITY; BETA(3)-ADRENOCEPTOR AGONIST; DETRUSOR OVERACTIVITY; AFFERENT ACTIVITY; URINARY; PATHOPHYSIOLOGY; DYSFUNCTION; MODULATION; MIRABEGRON;
D O I
10.1002/nau.25127
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims Micromotion is an autonomous intramural movement of the bladder, and is believed to be an initial step in the generation of urinary urgency. Therefore, controlling micromotion may be a novel target in overactive bladder (OAB) treatment. However, developing micromotion treatment has been limited by the absence of a standardized animal model. We attempted to create a micromotion animal model and investigated the effectiveness of a beta(3)-adrenoceptor agonist (CL316,243) on micromotion.Methods Bilateral major pelvic ganglia (MPGs) were excised in 18 male Sprague-Dawley rats, resulting in an almost completely denervated bladder. On postoperative Day 7, cystometry was performed. Rats were divided into three treatment groups: CL316,243; beta(3-)adrenoceptor antagonist (SR59230A) pretreated CL316,243; and a nonselective antimuscarinic agent (oxybutynin). Changes in micromotion were evaluated after the intra-arterial administration of each agent.Results Low-amplitude oscillations in intravesical pressure (micromotion) were observed 1 week after MPGs excision. Micromotion frequency significantly (p = 0.003) decreased (2.17 & PLUSMN; 3.54 times/5 min) with CL316,243 compared with vehicle (6.33 & PLUSMN; 1.97 times/5 min). Micromotion amplitude also decreased with CL316,243 (1.15 & PLUSMN; 1.93 cmH(2)O) compared with vehicle (5.96 & PLUSMN; 5.12 cmH(2)O), approaching conventional significance (p = 0.090). No significant decreases in frequency or amplitude were observed with oxybutynin treatment.Conclusions Systemic administration of the beta(3)-adrenoceptor agonist CL316,243 effectively controlled micromotion in bilateral MPGs-excised, almost completely denervated rat bladders. This result indicates that beta(3)-adrenoceptor agonist may affect the bladder directly, suggesting that it might be effective for overall OAB, regardless of the presence or level of neurological deficits. Bilateral MPGs-excised rats are considered a plausible micromotion animal model suitable for future research.
引用
收藏
页码:530 / 538
页数:9
相关论文
共 50 条
  • [21] Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects
    Iitsuka, Hiromi
    van Gelderen, Marcel
    Katashima, Masataka
    Takusagawa, Shin
    Sawamoto, Taiji
    CLINICAL THERAPEUTICS, 2015, 37 (05) : 1031 - 1044
  • [22] Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder
    Eltink, Charlotte
    Lee, Jennifer
    Schaddelee, Marloes
    Zhang, Wenhui
    Kerbusch, Virginie
    Meijer, John
    van Marle, Sjoerd
    Grunenberg, Nicole
    Kowalski, Donna
    Drogendijk, Ted
    Moy, Selina
    Iitsuka, Hiromi
    van Gelderen, Marcel
    Matsushima, Hiroshi
    Sawamoto, Taiji
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (11) : 838 - 849
  • [23] Role of the β3-adrenoceptor in urine storage in the rat:: Comparison between the selective β3-adrenoceptor agonist, CL316,243, and various smooth muscle relaxants
    Takeda, H
    Yamazaki, Y
    Akahane, M
    Igawa, Y
    Ajisawa, Y
    Nishizawa, O
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 293 (03): : 939 - 945
  • [24] Re: The Efficacy and Tolerability of the β3-Adrenoceptor Agonist Mirabegron for the Treatment of Symptoms of Overactive Bladder in Older Patients
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2015, 193 (03): : 947 - 947
  • [25] INHIBITORY EFFECTS OF CL316243, A BETA 3-ADRENOCEPTOR AGONIST, ON THE MYOGENIC ACTIVITIES AND ON THE MECHANOSENSITIVE AFFERENT ACTIVITIES IN THE OBSTRUCTED RAT BLADDER
    Watanabe, D.
    Aizawa, N.
    Suzuki, M.
    Kume, H.
    Igawa, Y.
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 : S189 - S190
  • [26] Video-urodynamic effects of mirabegron, a 3-adrenoceptor agonist, in patients with low-compliance bladder
    Kamei, Jun
    Furuta, Akira
    Akiyama, Yoshiyuki
    Niimi, Aya
    Ichihara, Koji
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Kume, Haruki
    Homma, Yukio
    Igawa, Yasuhiko
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (10) : 956 - 961
  • [27] Intracellular effect of β3-adrenoceptor agonist Carazolol on skeletal muscle, a direct interaction with SERCA
    Ramirez-Soto, Ibrahim
    Rodriguez, Eduardo
    Alvarez, Rocio
    Quiroz, Eugenio
    Ortega, Alicia
    CELL CALCIUM, 2019, 79 : 20 - 26
  • [28] Intracellular Effect of β3-Adrenoceptor agonist Carazolol on Skeletal Muscle, a Direct Interaction with SERCA
    Ramirez, Ibrahim A.
    Rodriquez, Eduardo
    Alvarez, Rocio
    Quiroz, Eugenio
    Ortega, Alicia
    BIOPHYSICAL JOURNAL, 2018, 114 (03) : 235A - 235A
  • [29] RELAXING EFFECT OF PHOSPHODIESTERASE INHIBITORS AND β3-ADRENOCEPTOR AGONIST IN AN EXPERIMENTAL MODEL OF DETRUSOR OVERACTIVITY
    Linhares, Bruno Lima
    Gonzaga-Silva, Lucio F.
    Regadas, Rommel P.
    Marinho, Lucas B.
    Cerqueira, Joao B. G.
    Moraes Filho, Manoel O.
    Santos, Claudia F.
    Nascimento, Nilberto R. F.
    Reges, Ricardo
    JOURNAL OF UROLOGY, 2017, 197 (04): : E320 - E321
  • [30] Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared With the Effects of Oxybutynin
    Aizawa, Naoki
    Homma, Yukio
    Igawa, Yasuhiko
    EUROPEAN UROLOGY, 2012, 62 (06) : 1165 - 1173